FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4245532406> ?p ?o ?g. }

• W4245532406 abstract "Introduction: Bleeding complications during acute coronary syndrome care are independent predictors of adverse outcomes. Patients presenting with ST-elevation myocardial infarction (STEMI) receiving warfarin therapy at home represent a management challenge especially in the absence of specific recommendations in current guidelines. Given the paucity of data, this study aims to describe the acute treatment patterns and bleeding risk in STEMI patients treated with primary percutaneous coronary intervention (PCI). Methods: We examined 120,270 STEMI patients treated with primary PCI at 586 ACTION Registry ® -GWTG TM hospitals between 2007- 2012, excluding patients who died within the first 24 hours. A total of 3,101 patients (2.6%) were on home warfarin. Antiplatelet and anticoagulant regimens within the first 24 hours of admission were compared between patients taking and those not taking warfarin at home. The association between home warfarin therapy and risk of in-hospital major bleeding was analyzed using multivariable logistic generalized estimating equations method. Results: STEMI patients on home warfarin were older and had higher prevalence of co-morbid conditions such as hypertension, diabetes, and renal disease compared with those not taking warfarin; at presentation only 35.6% of patients had INR ≥2.0. They were less likely to receive prasugrel and heparin, but more likely to receive clopidogrel and bivalirudin compared with those not on home warfarin (Table). Glycoprotein IIbIIIa inhibitors were also less commonly administered to patients taking warfarin at home (Table). Door-to-balloon ≤90 minutes for direct arrivals and ≤120 minutes for transfers were less likely to be achieved in patients on home warfarin (83.5% vs. 88.5%, p<0.0001 and 47.5% vs. 57.1%, p<0.0001, respectively). Home warfarin therapy was associated with significantly higher risk of in-hospital major bleeding (17.0% vs 10.1%; adjusted odds ratio 1.26 [1.13-1.40]). Conclusions: In STEMI patients treated with primary PCI, home warfarin therapy is associated with significant increase in the risk of in-hospital major bleeding despite the less frequent use of treatment regimens associated with higher bleeding risk. Future studies are needed to identify bleeding avoidance strategies in this high-risk population." @default.
• W4245532406 created "2022-05-12" @default.
• W4245532406 creator A5016149585 @default.
• W4245532406 creator A5023814427 @default.
• W4245532406 creator A5033163802 @default.
• W4245532406 creator A5033408468 @default.
• W4245532406 creator A5043643766 @default.
• W4245532406 creator A5071176966 @default.
• W4245532406 date "2013-05-01" @default.
• W4245532406 modified "2023-09-29" @default.
• W4245532406 title "Abstract 78: The Association of Home Warfarin Therapy with Acute Treatment Patterns and Bleeding Risk in Patients Presenting with ST-Elevation Myocardial Infarction: Results from the NCDR ^®" @default.
• W4245532406 doi "https://doi.org/10.1161/circoutcomes.6.suppl_1.a78" @default.
• W4245532406 hasPublicationYear "2013" @default.
• W4245532406 type Work @default.
• W4245532406 citedByCount "0" @default.
• W4245532406 crossrefType "journal-article" @default.
• W4245532406 hasAuthorship W4245532406A5016149585 @default.
• W4245532406 hasAuthorship W4245532406A5023814427 @default.
• W4245532406 hasAuthorship W4245532406A5033163802 @default.
• W4245532406 hasAuthorship W4245532406A5033408468 @default.
• W4245532406 hasAuthorship W4245532406A5043643766 @default.
• W4245532406 hasAuthorship W4245532406A5071176966 @default.
• W4245532406 hasConcept C126322002 @default.
• W4245532406 hasConcept C164705383 @default.
• W4245532406 hasConcept C194828623 @default.
• W4245532406 hasConcept C2776301958 @default.
• W4245532406 hasConcept C2777028646 @default.
• W4245532406 hasConcept C2777565915 @default.
• W4245532406 hasConcept C2777698277 @default.
• W4245532406 hasConcept C2777849778 @default.
• W4245532406 hasConcept C2779161974 @default.
• W4245532406 hasConcept C2780400711 @default.
• W4245532406 hasConcept C2780890252 @default.
• W4245532406 hasConcept C45393284 @default.
• W4245532406 hasConcept C500558357 @default.
• W4245532406 hasConcept C71924100 @default.
• W4245532406 hasConceptScore W4245532406C126322002 @default.
• W4245532406 hasConceptScore W4245532406C164705383 @default.
• W4245532406 hasConceptScore W4245532406C194828623 @default.
• W4245532406 hasConceptScore W4245532406C2776301958 @default.
• W4245532406 hasConceptScore W4245532406C2777028646 @default.
• W4245532406 hasConceptScore W4245532406C2777565915 @default.
• W4245532406 hasConceptScore W4245532406C2777698277 @default.
• W4245532406 hasConceptScore W4245532406C2777849778 @default.
• W4245532406 hasConceptScore W4245532406C2779161974 @default.
• W4245532406 hasConceptScore W4245532406C2780400711 @default.
• W4245532406 hasConceptScore W4245532406C2780890252 @default.
• W4245532406 hasConceptScore W4245532406C45393284 @default.
• W4245532406 hasConceptScore W4245532406C500558357 @default.
• W4245532406 hasConceptScore W4245532406C71924100 @default.
• W4245532406 hasIssue "suppl_1" @default.
• W4245532406 hasLocation W42455324061 @default.
• W4245532406 hasOpenAccess W4245532406 @default.
• W4245532406 hasPrimaryLocation W42455324061 @default.
• W4245532406 hasRelatedWork W12629805 @default.
• W4245532406 hasRelatedWork W14452866 @default.
• W4245532406 hasRelatedWork W1500053 @default.
• W4245532406 hasRelatedWork W1591285 @default.
• W4245532406 hasRelatedWork W16670499 @default.
• W4245532406 hasRelatedWork W20142860 @default.
• W4245532406 hasRelatedWork W22029071 @default.
• W4245532406 hasRelatedWork W24262587 @default.
• W4245532406 hasRelatedWork W4564605 @default.
• W4245532406 hasRelatedWork W890575 @default.
• W4245532406 hasVolume "6" @default.
• W4245532406 isParatext "false" @default.
• W4245532406 isRetracted "false" @default.
• W4245532406 workType "article" @default.